ACCELERON PHARMA INC. (NASDAQ:XLRN) Files An 8-K Other Events
Item 8.01 Other Events.
titled “Acceleron Provides Updated Results from Ongoing Phase 2
Study of Luspatercept in Myelodysplastic Syndromes at the 22nd
Congress of the European Hematology Association” and “Acceleron
Provides Updated Results from Phase 2 Studies of Luspatercept in
Beta-Thalassemia at the 22nd Congress of the European Hematology
Association.”
Exhibit 99.2, respectively, to this Current Report on Form 8-K
and are incorporated herein by reference.
|
Exhibit Number
|
Description of Exhibit
|
|
|
99.1
|
Press release of Acceleron Pharma Inc. dated June 23,
2017 |
|
|
99.2
|
Press release of Acceleron Pharma Inc. dated June 23,
2017 |
ACCELERON PHARMA INC ExhibitEX-99.1 2 xlrn-20170630form8xkex991.htm EXHIBIT 99.1 Exhibit Exhibit 99.1 Acceleron Provides Updated Results from Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 22nd Congress of the European Hematology Association- Results from ongoing trials demonstrate increases in hemoglobin and reductions in red blood cell transfusion burden sustained for more than 26 months -CAMBRIDGE,…To view the full exhibit click here About ACCELERON PHARMA INC. (NASDAQ:XLRN)
Acceleron Pharma Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutic candidates that are based on mechanisms, which the human body uses to regulate the growth and repair of its cells and tissues. Its therapeutic candidates are used to treat serious and rare diseases. The Company’s pipeline includes Luspatercept, Sotatercept, Dalantercept, ACE-083, ACE-2494, ACE-1332, ACE-3891, ACE-2798, ACE-2536 and ACE-2395. Luspatercept promotes red blood cell production. It is developing Sotatercept for the treatment of chronic kidney disease. Dalantercept treats cancers by inhibiting blood vessel formation by inhibiting signaling through the activin receptor-like kinase (ALK) 1 receptor. ACE-083 is for the treatment of focal muscle disorders. ACE-2494 is designed to treat systemic muscle disorders. ACE-3891, ACE-1332, ACE-2798, ACE-2536 and ACE-2395 are in preclinical stage of development.
